{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:05:32Z","timestamp":1789967132124,"version":"4.0.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the cost-utility of erenumab preventive treatment compared to no preventive treatment in adults with chronic migraine in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An individual-level microsimulation model was developed from the perspective of the Chinese health system. The model compared erenumab 70\u202fmg every 4\u202fweeks with no preventive pharmacotherapy plus usual acute and migraine-related medical care. The base-case time horizon was 52\u202fweeks, with 13\u202fcycles of 4\u202fweeks each. Clinical inputs were mainly derived from the DRAGON trial, which included Asian adults with chronic migraine. Week 12 monthly migraine days (MMDs) distributions were calibrated to reproduce the reported mean MMD and \u226550% MMD responder rate. Post-week 12 outcomes in the erenumab arm were extrapolated at the patient level according to treatment status and discontinuation. Costs included erenumab acquisition, acute medications, and migraine-related non-drug medical services. Outcomes included total costs, quality-adjusted life years (QALYs), the incremental cost-effectiveness ratio (ICER), and incremental net monetary benefit (INMB). One-way sensitivity analysis, probabilistic sensitivity analysis, a 12-week-horizon scenario analysis, and threshold price analysis were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the base case, erenumab preventive treatment generated 0.572 QALYs at a total cost of CNY 45,810.21, whereas no preventive treatment generated 0.557 QALYs at a total cost of CNY 4,281.59. The incremental cost was CNY 41,528.62, and the incremental QALY gain was 0.015. The ICER was CNY 2,830,387.52 per QALY gained. The INMB was CNY\u202f\u2212\u202f40,066.30 and CNY\u202f\u2212\u202f37,141.64 at willingness-to-pay (WTP) thresholds of 1\u00d7 and 3\u00d7 Gross Domestic Product (GDP) per capita, respectively. Sensitivity analyses and the 12-week scenario analysis supported the base-case conclusion. Threshold price analysis showed that erenumab would need to decrease to CNY 141.82 and CNY 386.81 per 70-mg box to be cost-effective at WTP thresholds of 1\u00d7 and 3\u00d7 GDP per capita, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From the Chinese health system perspective, erenumab as preventive treatment provides modest health gains for adults with chronic migraine but is unlikely to be cost-effective at its current price.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1878335","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:29:33Z","timestamp":1789964973000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-utility analysis of erenumab preventive treatment for chronic migraine in China"],"prefix":"10.3389","volume":"14","author":[{"given":"Lijiang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengying","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaolian","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]},{"name":"Research Center for Clinical Pharmacy, Zhejiang University","place":["Hangzhou, Zhejiang, China"]},{"name":"Department of Pharmacy, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s10194-024-01763-w","article-title":"Healthcare utilisation and economic burden of migraines among bank employees in China: a probabilistic modelling study","volume":"25","author":"Wei","year":"2024","journal-title":"J Headache Pain"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-020-01117-2","article-title":"Migraine treatment and healthcare costs: retrospective analysis of the China health insurance research association (CHIRA) database","volume":"21","author":"Yu","year":"2020","journal-title":"J Headache Pain"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"23","author":"Steinmetz","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-019-1048-2","article-title":"Burden of headache disorders in China, 1990-2017: findings from the global burden of disease study 2017","volume":"20","author":"Yao","year":"2019","journal-title":"J Headache Pain"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3969\/j.issn.1006-9852.2022.12.001","article-title":"Chinese guideline for the diagnosis and treatment of migraine (2022 edition)","volume":"28","year":"2022","journal-title":"Chin J Pain Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3331024241269735","DOI":"10.1177\/03331024241269735","article-title":"International headache society global practice recommendations for preventive pharmacological treatment of migraine","volume":"44","author":"Puledda","year":"2024","journal-title":"Cephalalgia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","article-title":"Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American headache society position statement update","volume":"64","author":"Charles","year":"2024","journal-title":"Headache"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3331024231206162","DOI":"10.1177\/03331024231206162","article-title":"Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the international headache society","volume":"43","author":"Aleksovska","year":"2023","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/wnl.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s10194-022-01514-9","article-title":"A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study","volume":"23","author":"Yu","year":"2022","journal-title":"J Headache Pain"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/head.14733","article-title":"Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: a post hoc analysis of the DRAGON study","volume":"65","author":"Wang","year":"2025","journal-title":"Headache"},{"key":"ref15","volume-title":"Erenumab for Preventing Migraine","year":"2021"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/aywa5297","article-title":"Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling","volume":"28","author":"Mistry","year":"2024","journal-title":"Health Technol Assess"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10194-024-01747-w","article-title":"Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis","volume":"25","author":"Pozo-Rosich","year":"2024","journal-title":"J Headache Pain"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","article-title":"A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine","volume":"23","author":"Khanal","year":"2022","journal-title":"J Headache Pain"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12889-021-12491-0","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"22","author":"Husereau","year":"2022","journal-title":"BMC Public Health"},{"key":"ref20","volume-title":"China Guidelines for Pharmacoeconomic Evaluations 2025: Chinese-English Version","year":"2025"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","article-title":"Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study","volume":"40","author":"Tepper","year":"2020","journal-title":"Cephalalgia"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","article-title":"Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study","volume":"41","author":"Gantenbein","year":"2021","journal-title":"Cephalalgia"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s10194-024-01775-6","article-title":"Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis","volume":"25","author":"Huang","year":"2024","journal-title":"J Headache Pain"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0333102418796842","article-title":"Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives","volume":"38","author":"Sussman","year":"2018","journal-title":"Cephalalgia"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","article-title":"Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS)","volume":"31","author":"Blumenfeld","year":"2011","journal-title":"Cephalalgia"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s10194-026-02389-w","article-title":"Methodology and baseline characteristics of the China migraine registry (CHIME): a nationwide, multi-center, prospective cohort study of 11,814 patients","volume":"27","author":"Ran","year":"2026","journal-title":"J Headache Pain"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s10194-025-02224-8","article-title":"Migraine management in Chinese headache centers: a national survey and the role of quality control inspections","volume":"26","author":"Ran","year":"2025","journal-title":"J Headache Pain"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s10194-025-02156-3","article-title":"Adherence status and influencing factors of acute and preventive pharmacotherapy among migraine patients in China","volume":"26","author":"Chen","year":"2025","journal-title":"J Headache Pain"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s10194-023-01587-0","article-title":"The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression","volume":"24","author":"Tepper","year":"2023","journal-title":"J Headache Pain"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1526-4610.2011.02061.x","article-title":"The prevalence and burden of primary headaches in China: a population-based door-to-door survey","volume":"52","author":"Yu","year":"2012","journal-title":"Headache"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40261-019-00827-z","article-title":"Cost-effectiveness analysis of Erenumab versus OnabotulinumtoxinA for patients with chronic migraine attacks in Greece","volume":"39","author":"Giannouchos","year":"2019","journal-title":"Clin Drug Investig"},{"key":"ref32","year":"2024"},{"key":"ref33","volume-title":"Statistical Communiqu\u00e9 of the People's Republic of China on the 2025 National Economic and Social Development","year":"2026"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1878335\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:29:35Z","timestamp":1789964975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1878335\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":33,"alternative-id":["10.3389\/fpubh.2026.1878335"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1878335","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1878335"}}